Chinese scientists discover gene associated with prostate cancer
The research reveals that PCSEAT is overexpressed in prostate cancer patients, indicating that PCSEAT may be a potential therapeutic target
Beijing: Chinese scientists have identified a new gene strongly associated with prostate cancer, offering new methods for diagnosis and treatment of the disease. The newly identified biomarker, PCSEAT, was discovered by scientists from Suzhou Institute of Biomedical Engineering and Technology, state-run Xinhua news agency reported.
The research reveals that PCSEAT is overexpressed in prostate cancer patients, indicating that PCSEAT may be a potential therapeutic target. The research was published in the journal Biochemical and Biophysical Research Communications in May.
Based on the research, they have developed an early diagnosis for prostate cancer and applied for a patent. The application can significantly improve the accuracy of prostate cancer diagnosis and reduce the cost of diagnosis and treatment. China has seen increasing cases of prostate cancer in recent years.
- Now, you can lace new Nike Adapt BB shoes with your smartphone
- Court asks govt to retest samples of Ghaziabad-based firm’s polio vaccine
- Scientists develop data framework for early detection of Alzheimer’s disease
- Isro set to launch Chandrayaan-2 by March-April
- Is dental floss harmful for your body? Read what the latest study finds
Editor's Picks »
- Opinion | The ‘stuck’ Naga peace talks need a reimagining
- #10YearChallenge: The meme game that’s taking the Internet by storm
- Theresa May government faces no-confidence vote after Brexit defeat
- US retailer Sears saved from the brink for time being: reports
- Sabarimala row: After the Left’s lakhs-strong ‘Women’s Wall’, the Right’s to rally lakhs of pro-ban supporters in Kerala
- Why Tata Motors’ Project Charge at JLR is failing to recharge its shares
- Outlook on global profit growth worst since 2008 financial crisis
- Q3 results: ICICI Securities loses its retail broking crown
- High drug approvals to keep up pricing pressure for pharma firms
- Roads sector: Toll collections set to surge, but risks loom for developers